Navigation Links
Discovery provides new drug targets for malaria cure

Researchers are a step closer to developing new antimalarial drugs after discovering the normal function of a set of proteins related to the malaria parasite protein, which causes resistance to the front-line drug chloroquine. The findings also provide a novel tool for studying the malarial chloroquine-resistance factor.

The study examined transporter proteins which are known to move compounds around the cell. The genes for these proteins are present in plants as well as the malaria parasite Plasmodium falciparum (known as clt and PfCRT respectively), so researchers used the model plant Arabidopsis to reveal that these proteins normally transport glutathione, an antioxidant which protects the cell from stresses.

In the malaria parasite (a single cell organism), this type of transporter protein has mutated so that it no longer functions normally, enabling it to remove the drug chloroquine from its cell and survive.

Plasmodium falciparum is the most dangerous of the malaria infections being transmitted by the female Anopheles mosquito. It has the highest rates of complications and mortality and is responsible for up to one million deaths per year, mostly children in Africa under the age of five. The evolution of drug-resistant Plasmodium strains, especially those resistant to chloroquine, has had major impacts on global public health. The economic toll is also huge with malaria infection destroying more than 1% of African GPD.

The work was led by Dr Spencer Maughan who began researching these genes in Prof. Chris Cobbett's lab in the Department of Genetics at the University of Melbourne and involved an international team from the Universities of Melbourne, Cambridge (UK), Heidelberg (Germany), Liverpool (UK) and Rothamsted Research (UK). It will be published in the prestigious international journal PNAS this week.

"Our findings set in motion the chance of reclaiming the efficacy of chloroquine which could turn the tide on the war against malaria and ultimately may help save millions of lives," said Dr Maughan.

"The transporter is normally essential to the survival of the malaria parasite and when mutated, provides the extra advantage of removing the drug chloroquine from its cell.

"We hope that understanding the normal role of the transporter in plants will be a key step in malaria research. Unlike in the plant, if the gene for the transporter is inactivated in malaria, the parasite dies, preventing more study into its role. The plant could therefore provide a useful tool in malaria research."

"These results describe the first missing link in understanding this class of proteins and could provide a two-pronged treatment approach- preventing malaria removing chloroquine from its cell and enabling the design of new drugs based on the shape of glutathione."


Contact: Nerissa Hannink
University of Melbourne

Related biology technology :

1. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
2. miRagen announces discovery of key microRNA implicated in Lou Gehrigs disease
3. MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products
4. Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities
5. Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery
6. Physicists at UC Santa Barbara make discovery in quantum mechanics
7. New discovery reveals fate of nanoparticles in human cells
8. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
9. CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc.
10. StoredIQ Shares Expertise at IQPCs eDiscovery Pharma, Biotech and Medical Device Conference
11. Alzheimers Drug Discovery Foundation and the Lewy Body Dementia Association Invite Scientists to Apply for LBD Grant Award Program
Post Your Comments:
(Date:11/30/2015)... -- Champions Oncology, Inc. (CSBR), engaged in the development of ... and use of oncology drugs, today announced that ... at the LD MICRO Investor Conference on Wednesday, December ... conference, held at the Luxe Sunset Bel Air Hotel ... feature 200 small/micro-cap companies and is expected to host ...
(Date:11/30/2015)...  HUYA Bioscience International, the leader in accelerating global ... today announced it has signed a Memorandum of Understanding ... collaboration between KDDF and HUYA with the ultimate goal ... for the global market. China,s ... innovative preclinical and clinical stage compounds. The company advances ...
(Date:11/30/2015)... Germany , November 30, 2015 ... Vienna, Austria to be held December 1-4, ... in Vienna, Austria to be ... owned subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), announced ... Therapy Suite at the 3rd European Congress of NeuroRehabilitation ...
(Date:11/30/2015)... PETACH TIKVAH, Israel , Nov. 30, 2015 ... ), a leading developer of adult stem cell technologies for ... Therapeutics Ltd., has been awarded an additional grant of approximately ... Chief Scientist (OCS). This grant, the second this year, brings ... to approximately $1.8 million (approximately NIS7 million).  ...
Breaking Biology Technology:
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
(Date:10/26/2015)... and LAS VEGAS , ... Nok Labs , an innovator in modern authentication and ... today announced the launch of its latest version of ... platform enabling organizations to use standards-based authentication that supports ... Nok S3 Authentication Suite is ideal for organizations deploying ...
Breaking Biology News(10 mins):